InvestorsHub Logo

db7

Followers 221
Posts 39697
Boards Moderated 0
Alias Born 09/02/2003

db7

Member Level

Re: None

Wednesday, 02/12/2020 5:44:51 PM

Wednesday, February 12, 2020 5:44:51 PM

Post# of 108
Peer Comparison(?) I realize they are NOT apples to apples but all diagnostic testing disruptors specifically mentioned in DMTK's latest presentation


Colorectal, Exact Sciences 'EXAS' @ $95.85 , MarketCap: ~$14,000,000,000
Lung, Guardant Health 'GH' @ $82.80 , MarketCap: ~$ 7,800,000,000
Prenatal, Natera 'NTRA' @ $36.51 , MarketCap: ~$ 2,900,000,000
Breast, Genomic Health 'GHDX' @ $63.44*, MarketCap: ~$ 2,400,000,000
Thyroid, Veracyte 'VCYT' @ $26.54 , MarketCap: ~$ 1,300,000,000
Heart, CareDx 'CDNA' @ $25.07 , MarketCap: ~$ 1,100,000,000
Skin, DermTech 'DMTK' @ $13.55 , MarketCap: ~$ 148,000,000

* GHDX quote prior to becoming part of EXAS


IMO, the future is bright for our still under the radar DMTK...










Please verify my dd..etc..etc....








-------------------------------------------------------------------

All posts are strictly my opinion and are not buy or sell recommendations.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DMTK News